<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336366">
  <stage>Registered</stage>
  <submitdate>30/12/2010</submitdate>
  <approvaldate>10/01/2011</approvaldate>
  <actrnumber>ACTRN12611000028909</actrnumber>
  <trial_identification>
    <studytitle>Day 3 versus day 5 embryo transfer in high-responding women undergoing in vitro fertilization: a randomized controlled trial</studytitle>
    <scientifictitle>Day 3 versus day 5 embryo transfer in high-responding women on pregnancy outcomes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Day of embryo transfer in women undergoing in vitro fertilization</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Embyro transfer on Day 5 post oocyte pick-up and intracytoplasmic sperm injection (i.e. fertilization). Number of embryos will depend on number available on day of transfer but the target for this group is 2 embryos per transfer.</interventions>
    <comparator>Embryo transfer on Day 3 post oocyte pick-up and intracytoplasmic sperm injection (i.e. fertilization). Number of embryos will depend on number available on day of transfer but the target for this group is 3 embryos per transfer.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical pregnancy rate as assessed using quantitative assessment serum Beta human Chorionic Gonadotropin (B-hCG) levels.</outcome>
      <timepoint>2 weeks after embryo transfer</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Live-birth/ ongoing pregnancy rate using follow-up telephone calls until expected time of delivery.</outcome>
      <timepoint>&gt;12 weeks after embryo transfer to determine ongoing pregnancies and at 9 months to determine live-births.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* womens age &lt;=35 years, with regular cycles (24 to 35 days)
* day 3 follicle stimulating hormone (FSH) &lt;9.5 IU/L
* antral follicle count (AFC) &gt;6
* E2 levels &gt;3,000 pg/mL &amp; endometrial thickness &gt;=8 mm on the day of hCG administration
* at least four grade one embryos (i.e. regular symmetrical blastomeres with no fragmentation) on day 3 after retrieval</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>* women's age &gt;35 years
* &lt;4 grade one embryos on day 3 after retrieval</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment will be performed using 200 identical dark-sealed envelopes, prepared by one of the investigators and kept in the unitâ€™s pharmacy.</concealment>
    <sequence>On day 3, included women will be randomized into two groups using block randomization.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eman Elgindy, MD</primarysponsorname>
    <primarysponsoraddress>Department of Obstetrics and Gynecology
Zagazig University School of Medicine
Zagazig
Sharkia Governate
Postal Code: 44519</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Eman Elgindy, MD</fundingname>
      <fundingaddress>Department of Obstetrics and Gynecology
Zagazig University School of Medicine
Zagazig
Sharkia Governate
Postal Code: 44519</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this trial is to test the hypothesis that delaying embryo transfer to blastocyst stage may increase the probability of pregnancy in high responders undergoing their first ICSI cycles using the long agonist protocol.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethical Committee for Research, Al-Banoon Fertility Center</ethicname>
      <ethicaddress>Al-Banoon Fertility Center
7 El Reyad St.
Zagazig
Sharkia Governate
Postal Code: NA</ethicaddress>
      <ethicapprovaldate>1/08/2008</ethicapprovaldate>
      <hrec>NA</hrec>
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eman Elgindy, MD</name>
      <address>Department of Obstetrics and Gynecology
Zagazig University School of Medicine
Zagazig
Sharkia Governate
Postal Code: 44519</address>
      <phone>+20-2-2692-2453</phone>
      <fax>+20-12-749-1143</fax>
      <email>eaelgindy@zu.edu.eg</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eman Elgindy, MD</name>
      <address>Department of Obstetrics and Gynecology
Zagazig University School of Medicine
Zagazig
Sharkia Governate
Postal Code: 44519</address>
      <phone>+20-2-2692-2453</phone>
      <fax>+20-12-749-1143</fax>
      <email>eaelgindy@zu.edu.eg</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eman Elgindy, MD</name>
      <address>Department of Obstetrics and Gynecology
Zagazig University School of Medicine
Zagazig
Sharkia Governate
Postal Code: 44519</address>
      <phone>+20-2-2692-2453</phone>
      <fax>+20-12-749-1143</fax>
      <email>eaelgindy@zu.edu.eg</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>